Magenta Therapeutics Stock Forecast, Price & News

Magenta Therapeutics' stock was trading at $9.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MGTA shares have decreased by 23.5% and is now trading at $7.01.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Magenta Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Magenta Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Magenta Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Magenta Therapeutics.

Magenta Therapeutics, Inc. (NASDAQ:MGTA) issued its earnings results on Thursday, November, 5th. The company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.08.
View Magenta Therapeutics' earnings history.

5 Wall Street analysts have issued 1 year price targets for Magenta Therapeutics' shares. Their forecasts range from $15.00 to $22.00. On average, they anticipate Magenta Therapeutics' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 171.0% from the stock's current price.
View analysts' price targets for Magenta Therapeutics.

Magenta Therapeutics saw a increase in short interest in October. As of October 30th, there was short interest totaling 1,870,000 shares, an increase of 16.1% from the October 15th total of 1,610,000 shares. Based on an average daily volume of 216,700 shares, the days-to-cover ratio is presently 8.6 days. Approximately 6.4% of the company's stock are short sold.
View Magenta Therapeutics' Short Interest.

Some companies that are related to Magenta Therapeutics include MacroGenics (MGNX), Rhythm Pharmaceuticals (RYTM), Athenex (ATNX), Phathom Pharmaceuticals (PHAT), Ocular Therapeutix (OCUL), Kiniksa Pharmaceuticals (KNSA), Endo International (ENDP), Epizyme (EPZM), Intercept Pharmaceuticals (ICPT), Cytokinetics (CYTK), Travere Therapeutics (RTRX), Constellation Pharmaceuticals (CNST), Zogenix (ZGNX), Amneal Pharmaceuticals (AMRX) and Pliant Therapeutics (PLRX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP).

(MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Magenta Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.66%), UBS Asset Management Americas Inc. (1.26%), State Street Corp (0.73%), Morgan Stanley (0.57%), Principal Financial Group Inc. (0.50%) and Truist Financial Corp (0.27%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, Jason Gardner, John C Davis Jr and Michael P Cooke.
View institutional ownership trends for Magenta Therapeutics.

MGTA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., and State Street Corp. Company insiders that have sold Magenta Therapeutics company stock in the last year include Jason Gardner, John C Davis Jr, and Michael P Cooke.
View insider buying and selling activity for Magenta Therapeutics.

MGTA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Truist Financial Corp, Squarepoint Ops LLC, Cubist Systematic Strategies LLC, Arrowstreet Capital Limited Partnership, ProShare Advisors LLC, and UBS Asset Management Americas Inc..
View insider buying and selling activity for Magenta Therapeutics.

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGTA stock can currently be purchased for approximately $7.01.

Magenta Therapeutics has a market capitalization of $338.62 million. The company earns $-76,770,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Magenta Therapeutics employs 72 workers across the globe.

The official website for Magenta Therapeutics is www.magentatx.com.

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]